NCT05646199View on ClinicalTrials.gov

Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Metformin

Participants will receive metformin

DRUG

Semaglutide Injectable Product

Participants in this group will receive injectable Semaglutide

Trial Locations (1)

HU32RW

Hull University Teaching Hospitals NHS Trust, Hull

All Listed Sponsors
lead

University of Hull

OTHER

NCT05646199 - Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) | Biotech Hunter | Biotech Hunter